pistoia presentation bio it-worldexpo 21april2010
DESCRIPTION
TRANSCRIPT
![Page 1: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/1.jpg)
pistoiaalliance.org
Ramesh Durvasula, Ph.D.Communications Officer, Pistoia AllianceDirector, Chemistry Informatics, BMS
BioIT World 2010
The Pistoia Alliance
A Construct for Pre-competitive Collaboration and Open Innovation
![Page 2: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/2.jpg)
Agenda
• Origins of Pistoia– History– Industry Drivers– Technology Trends
• Scope and Operations of Pistoia– Mission, Membership, Governance– Projects and Deliverables
• Discussion
![Page 3: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/3.jpg)
Industry Driver: Externalization
DA
TA C
RO
BIO
CR
OC
HE
M C
RO
PHA
RM
ASelectivelyIntegrated
Model
Fully InternalModel
Cost pressures, disruptive technologies, and other forces often drive business processes to be externalized.
![Page 4: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/4.jpg)
Emerging Net-centric PharmaProcesses
PHARMA1
CRO2
CRO1
CRO3
PHARMA2
PHARMA3
CRO4
![Page 5: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/5.jpg)
Inconsistent Semantics degrade Effective Communication
A
B
C
The result from our proprietary assay is “B”
But we only record numbers in our assays!!
PHARMA
CRO
![Page 6: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/6.jpg)
Image/quote from Abdul-Malik Shakir
Greater Challenge: Unknown Semantic Collisions
Revealing assumptions is an essential component of effective communication.
![Page 7: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/7.jpg)
Opportunity: Changing Tech Landscape
More Robust Technologies• Web 2.0 / 3.0• Services-Oriented Architecture• Software-as-a-Service• Open Source Initiatives
More Robust External Content• Publicly available chem and bio sources• Richer literature content• Academic Sources of Tools and Data
![Page 8: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/8.jpg)
The Path Forward:Standardize, Simplify, Centralize
• Standardize our interfaces and messages
• Simplify our cross-industry architectures and support models
• Centralize services to reap economies of scale and scope
![Page 9: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/9.jpg)
Background—How it all started
• In Pistoia, Italy
• Meeting of GSK, AZ, Pfizer and Novartis—identified similar challenges and frustrations in discovery informatics
9
![Page 10: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/10.jpg)
Pistoia Mission
• The Mission– Pistoia will standardize and streamline data
interchange in life science R&D.• The Method
– Precompetitive collaboration between life science, academia, and commercial partners.
• The Result– Standardization will drive down the cost of data
exchange, cloud computing, and process outsourcing.• The Benefit
– Informatics organizations can streamline commodity services, and focus investment on innovation in R&D.
![Page 11: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/11.jpg)
Benefits of Pistoia
• R&D Organizations– Optimized investments
• e.g. reduction of redundant investments across industry– Increased agility to leverage global R&D
• Rapid integration, streamlined data interchange and analysis
• Informatics Solution Providers– New markets and business models– Reduced cost-of-entry to markets– Reduction of customized solutions, leading to
higher margins
![Page 12: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/12.jpg)
Pistoia Membership
updated: April 2010
![Page 13: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/13.jpg)
Pre-competitive Space in the Technology Lifecycle
Precompetitive SpaceOpportunities for Standards
Legacy
Commodity
Mainstream
Innovation
Experiment
![Page 14: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/14.jpg)
Crossing the Chasm
• Pistoia is the BRIDGE to cross the chasm to a more agile pre-competitive environment
STANDARDIZE SIMPLIFY CENTRALIZE
PISTOIA MEMBERS SUPPLIERS
![Page 15: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/15.jpg)
Learn from Other Industries
Transportation
Geospatial
Automotive
ClinicalRetail
Banking
Healthcare
![Page 16: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/16.jpg)
16
Phase III
Scope of Pistoia Efforts
Phase ILead OptLead IDHit IDTarget ID
Which Target? Which Compound?Which Disease?What Biomarkers?
Disease AssociationBioprocess AssocDruggability‘On Target’ Safety RiskValidation ToolsCompetitive PositionVariant Selection…
DMPK Properties?BioAssay DevelopmentActivity-Dose studies?‘Off Target’ Safety Risk?Synthesis routes?Competitive Position?…
CD positioning?Safety Biomarkers?Efficacy Biomarkers?…
Genome/Genetic Data
Sequence Data
Expression Data
Genome/Genetic Data
Pathway Data
Patent Data
Pharmacology Data
Literature Data
Structural Data
Phase II
![Page 17: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/17.jpg)
17
Pistoia Standards Process
Technical & Standards Teams
Governance & Strategy Board
Operational Team
Life ScienceCommunity
Governance & Operations
Software and Service Providers
Pharma/BioTech/Agro
Not for Profit (e.g. IMI, EBI)
propose,comment
publish
coordinate
Pistoia Working Groups
![Page 18: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/18.jpg)
Current, Active Pistoia Projects
• Semantic Enrichment of Scientific Literature– An open knowledge brokering framework standard which will
reduce the costs of integration from disparate sources.
• Sequence Services– A standard service to provide access to public, private &
commercial data & tools, that will enable scientists to search, store & analyse all their sequence based data in a single web interface.
• ELN Query Service– A query service standard applicable for use with data types
commonly found in electronic lab notebooks
![Page 19: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/19.jpg)
Assertion & Meta Data MgmtTransform / TranslateIntegrator
Service Layer
Corpus 1
ConsumerFirewall
SupplierFirewall
Proprietary Service Broker
MultipleConsumers
SESL: Biomedical Knowledge Service Framework
Db 2
Db 3
Db 4
Corpus 5
Std PublicVocabularies
KnowledgeApplications
TargetDossier
CompoundDossier
DiseaseDossier
ContentSuppliers
Effort required to fit DBs to service layer
BusinessRules
NetworkViz
OpenStds
Common Service Broker
![Page 20: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/20.jpg)
A Production SESL Service
Broker Org #4Broker Org #3Broker Org #2
Corpus 1
ConsumerSide
SupplierSide
Db 2
Assertion & Meta Data Mgmt
Transform / Translate
Integrator
Service Layer Std PublicVocabularies
BusinessRules
Assertion & Meta Data Mgmt
Transform / Translate
Integrator
Service Layer Std PublicVocabularies
BusinessRules
Assertion & Meta Data Mgmt
Transform / Translate
Integrator
Service Layer Std PublicVocabularies
BusinessRules
Assertion & Meta Data Mgmt
Transform / Translate
Integrator
Service Layer Std PublicVocabularies
BusinessRules
Broker Org #1
Db 3
Corpus 4
Corpus 5
Db 6
Db 7
Corpus 8
Corpus 9
Db 10
Db 11
Corpus 12
Corpus 13
Db 14
Db 15
Corpus 16
Disease Dossier
License
Exemplar Application
![Page 21: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/21.jpg)
SESL Mock Up Slide 1
Gene:
Disease: Relationship:
Constraint:
abcAnyDiabetesSpecies: AnyTissue: Any
![Page 22: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/22.jpg)
abc1Gene R’ship Disease
Co-occursSpecies
Diabetes MusEvidencePaper UID:1234
abc1 Up-Reg Diabetes Homo ArrayExpress: XXXabc2 Co-occurs Diabetes Homoabc13 Co-occurs Diabetes Musabc7 Mutation Diabetes Rattusabc1 Co-occurs Diabetes Musabc1 Co-occurs Diabetes Homo
Paper UID:1344Paper UID:1314OMIMI: XXXPaper UID:45643Paper UID:2143
Export to Network View Pivot on Assertion
1234567
abc1 Co-occurs Diabetes Mus Paper UID:12048
SESL Mock Up Slide 2
![Page 23: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/23.jpg)
abc1Gene R’ship Disease
Co-occursSpecies
Diabetes MusSupporting Evidence3
abc7 Mutation Diabetes Rattus 1
Export to Network View Return
1
abc1 Up-Reg Diabetes Homo 13abc1 Co-occurs Diabetes Homo 12
4
abc2 Co-occurs Diabetes Rattus 1abc13 Co-occurs Diabetes Mus 15
6
SESL Mock Up Slide 3
![Page 24: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/24.jpg)
Current SESL Participants
AstraZeneca FundingGSK FundingRoche FundingPfizer FundingUnilever FTEsEuropean Bioinformatics Institute FTEs & HostingOxford University Press ContentNature Publishing Group ContentElsevier ContentRoyal Society of Chemistry Content
![Page 25: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/25.jpg)
If you want to go fast, go alone. If you want to go far, go together.
www.pistoiaalliance.org
![Page 26: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/26.jpg)
Backup Slides
![Page 27: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/27.jpg)
Where We Are
![Page 28: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/28.jpg)
Who we Are: Board of Directors
GSKAZNovartisPfizerLundbeckBMSRoche
AccelrysChemAxonSymyxCambridgeSoftInfosysThomson Reuters
![Page 29: Pistoia presentation bio it-worldexpo 21april2010](https://reader034.vdocuments.net/reader034/viewer/2022051612/54c21bba4a795988208b45ee/html5/thumbnails/29.jpg)
Pistoia Membership Levels
• Core Member ($15,000)– Those organisations wishing to strongly influence the strategy &
direction of the Alliance– Have a majority on the Governance & Strategy Board– Pharma, Life Science, Chemicals/Biologics primary business focus
• Participating Member ($10,000)– Those wishing to influence the technical outcomes– Access to Governance & Strategy Board member openings– Technical & Standards Team voting
• Contributing Member (free)– Technical & Standards Team voting member– Working Group participation – Offer opinions on technical issues
Based around the experiences of: http://www.consortiuminfo.org/